Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Venus Medtech (Hangzhou) Inc.
  6. News
  7. Summary
    2500   CNE100003PJ8

VENUS MEDTECH (HANGZHOU) INC.

(2500)
  Report
Delayed Hong Kong Stock Exchange  -  04:08:15 2023-05-25 am EDT
8.070 HKD   -2.54%
03/31Venus Medtech Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
03/04Confirmatory clinical trial of Liwen RF™ ablation system in China concluded
AQ
03/03Venus Medtech Completes Patient Enrollment for Confirmatory Trial of Liwen RF Ablation System
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Venus Medtech Hangzhou : VOLUNTARY ANNOUNCEMENT UNAUDITED OPERATING STATISTICS FOR THE PERIOD FROM JANUARY 1, 2021 TO JUNE 30, 2021

07/26/2021 | 05:18am EDT

Pursuant to the Codes on Takeovers and Mergers and Share Repurchases ('Takeovers Codes'), a copy of each document to be displayed under Note 1 to Rule 8 of the Takeovers Codes must be provided by the issuer of the offer document or offeree board circular, as appropriate, to Securities and Futures Commission ('SFC') for display on the SFC's website. To access these documents on display, you can either click this link https://www.sfc.hk/dod/jsp/EN/DoDmain.jsp or click the View Documents on Displaybutton next to the subject title of the offer document or offeree board circular.

Some of the files are prepared in the portable document format and viewing them requires Adobe(R) Reader(R) which can be downloaded free of charge.

Disclaimer

Venus MedTech HangZhou Inc. published this content on 26 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 July 2021 09:17:06 UTC.


ę Publicnow 2021
All news about VENUS MEDTECH (HANGZHOU) INC.
03/31Venus Medtech Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
03/04Confirmatory clinical trial of Liwen RF™ ablation system in China concluded
AQ
03/03Venus Medtech Completes Patient Enrollment for Confirmatory Trial of Liwen RF Ablation ..
MT
03/03Venus Medtech Inc. Announces Completion of Full Patient Enrollment for Confirmatory Cli..
CI
01/30Venus Medtech Inc. Announces Board Changes
CI
2022Venus Medtech Inc. Announces Resignation of Lim Hou-Sen as an Executive Director and Ni..
CI
2022Venus Medtech to showcase its structural heart treatments at London Valves 2022
AQ
2022Venus Medtech to showcase its structural heart treatments at London Valves 2022
PR
2022Venus Medtech to showcase its structural heart treatments at London Valves 2022
AQ
2022China to Exclude Medical Devices From Bulk-Buying Program
MT
More news
Financials
Sales 2023 627 M 88,6 M 88,6 M
Net income 2023 -376 M -53,1 M -53,1 M
Net cash 2023 530 M 75,0 M 75,0 M
P/E ratio 2023 -8,52x
Yield 2023 -
Capitalization 3 191 M 451 M 451 M
EV / Sales 2023 4,25x
EV / Sales 2024 3,10x
Nbr of Employees 1 028
Free-Float 71,7%
Chart VENUS MEDTECH (HANGZHOU) INC.
Duration : Period :
Venus Medtech (Hangzhou) Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VENUS MEDTECH (HANGZHOU) INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 7,29 CNY
Average target price 14,26 CNY
Spread / Average Target 95,6%
EPS Revisions
Managers and Directors
Zhen Jun Zi Executive Director & General Manager
Hai Yue Ma Chief Financial Officer & Joint Secretary
Min Zeng Chairman
Min Shao Chairman-Supervisory Board
Hou-Sen Lim Chief Operating Officer & Chief Technology Officer
Sector and Competitors
-40% off: Our subscriptions help you unlock hidden opportunities!
Subscribe
fermer